The new hair loss treatment shows the promise: the paid volunteers needed to try it

The head is up!

A new potential treatment for androgenetic alopecia, also known as the baldness of male patterns, is making waves as a national clinical trial to test their safety and efficiency.

Defenders are abuse of VDPHL01, a non -hormonal pill that shows a promise to restore hair without the hassle of topical treatments and potentially severe side effects of hormonal medication.

“I emphasize non -hormonal because the only oral treatment approved by the FDA for pattern hair loss has a hormonal mechanism of action and is associated with possible hormonal side effects such as erectile dysfunction, the decrease in libido and suicide thoughts,” said Dr. Neil Sadick in the post.

“Topical options also have high rates of discontinuation, as they can be messy and annoying to apply,” Sadick, a clinical professor of Dermatology at Weill Cornell Medical College, added.

There is no care for androgenetic alopecia, even because it affects more than 80 million Americans. The United States Food and Drug Administration has approved topic minoxidil (also known as Rogaine) and Oral Finasteride (brand branding) to treat hair loss.

Here is what you need to know about VDPHL01.

What is VDPHL01?

VDPHL01 is affected by Veradermics, a New Haven -based biopharmaceutical company, Conn., Which announced in December that it raised $ 75 million to finance the new trial.

Veradermics recently developed a “modified” oral minoxidile tablet. Sadick refused to say if VDPHL01 contains minoxidil.

“The judgment sponsor, Veradermics, is to choose not to disseminate additional information on drug formulation at this time,” Sadick said.

“I can tell you that VDPHL01 has a single profile unlike current FDA approved treatments, which are associated with heart activity and unwanted side effects,” he continued.

VDPHL01 is being studied as a pill once or twice a day. Sadick said that phase 2 preliminary data revealed the hair growth up to two months after treatment. He said that this “encouraging” data should be available.

Veradermics hopes to submit an approval in a year after its conclusion, if they go well.

How does VDPHL01 differ from other treatments?

Finasteride, which was sold as Proscar or Own, was approved by the FDA in the 1990’s. It is estimated that 2.6 million people took Finasteride in 2022.

The pill prevents The testosterone became another hormone called dihydrotestosterone (DHT). High levels of DHT can cause hair follicles to reduce, causing hair loss.

While Finasteride reduces hair loss and promotes hair growth, it is only intended for men and can cause erectile dysfunction, decrease in sexual unit and depression, among other potential side effects.

The FDA, meanwhile, approved oral minoxidil in the 1970’s to treat high blood pressure and topical minoxidil in the 1980’s for hair loss.

Minoxidil increases blood flow to hair follicles, stimulating hair growth.

The OTC MED’s side effects include irritation of the scalp, unwanted facial hair growth, chest pain, heartbeat and dizziness.

Sadick, when asked about the possible side effects of VDPHL01, Sadick said that the conversation is “better between a study researcher and a possible test participant.”

Who can participate in the VDPHL01 trial?

Sadick’s Manhattan Office, Sadick Dermatology, is one of the 44 North -Americans involved in the VDPHL01 phase 2/3 phase clinical trial.

The goal is to register about 480 men at all sites of study.

Sadick is looking for healthy men between the ages of 18 and 65 living in the New York area and experiences pattern hair loss. Applicants must be willing to keep their hair at least a quarter of an inch long throughout the study.

The selected ones will be compensated for their participation, which involves 13 visits to the Dermatology of Sadick for approximately 13 months. Patients registered will receive VDPHL01 or a placebo. Visit phlstudy.com or call at (212) 772-7242 for more information or register.

VDPHL01 is also being studied in women, with a clinical trial of phase 3 that is expected to begin later this year.